Hisamitsu buys remaining 95.1% of Noven for $408mm in cash
Executive Summary
Hisamitsu Pharmaceutical, a 162-year-old company that claims to be the largest therapeutic patch manufacturer in the world, has agreed to acquire the remaining 95.1% of Noven Pharmaceuticals (drug delivery technologies) that it does not already own for about $408mm. Noven investors will receive $16.50 in cash (a 17% premium) for each share. Hisamitsu initially gained a 4.9% stake in 2002.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Transdermal
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice